Research confirms benefits of side-actuated nasal spray

Published: 8-Feb-2010
Ingredients Drug Delivery Research & Development Pharmaceutical

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

Research confirms benefits of side-actuated nasal spray
Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.

The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.

Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.

The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.




See more

You may also like

Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Read more
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline

Trending Articles

  1. Takara Bio extends biomanufacturing capabilities with custom enzyme manufacturing lab Its Gothenburg facility now has a manufacturing lab that can produce customised molecular biology products such as PCR and qPCR enzymes
  2. Grünenthal joins genetic medicine cluster CNATM to advance RNA therapeutics The pain specialist has joined the Cluster for Nucleic Acid Therapeutics Munich to strengthen its oligonucleotide drug discovery capabilities and accelerate the development of genetic medicines for neurological diseases
  3. Kindeva appoints Brok Weichbrodt as Chief Transformation Officer to accelerate growth strategy and commercial excellence Kindeva, a global drug delivery Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brok Weichbrodt as Chief Transformation Officer to strengthen operational excellence, scale execution, and accelerate growth as the company enters the next phase of its value creation plan
  4. Entact Bio appoints John G. Houston, Ph.D., to its Board of Directors A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Manufacturing
DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

Brings decentralised, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market
Manufacturing
ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products
Design & Build
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Precision medicine and the fight to revive neuroscience R&D

Precision medicine and the fight to revive neuroscience R&D

In discussion with Dr Kevin Robinson (KSR), Neurvati’s Dr Bruce Leuchter (BL) explores how biology-led development, better diagnosis and rare disease infrastructure could help to unlock stalled neuroscience programmes
Subscribe now